The JADE study will be evaluating BI 1584862, an investigational oral compound that targets inflammation and preserves ...

We look forward to supporting innovation in the life science industry by continuing to deliver effective risk transfer ...

IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

The first trial site has been initiated in the pivotal phase 3 OVATION 3 study which will investigate IMNN-001 for newly ...

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and ...

The average age of the remaining 42,000 women in the Women’s Health Initiative is 87 years. Experts say new longitudinal ...

Q1 2025 Earnings Call Transcript May 7, 2025 Geron Corporation beats earnings expectations. Reported EPS is $-0.03, ...

Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q ...

Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET. Company Participants. Stephanie Fagan - Chief Corporate Affairs Officer Rob Bar ...